PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsOlaparib extends life of ovarian cancer patients with BRCA1/2

BioNews

Olaparib extends life of ovarian cancer patients with BRCA1/2

Published 23 April 2021 posted in News and appears in BioNews 1092

Author

Hannah Flynn

Science Editor
PET BioNews

Cancer treatment olaparib has been shown to extend the life of relapsed ovarian cancer patients with mutations in BRCA1 and BRCA2, by nearly 13 months, when used as a maintenance therapy...

Cancer treatment olaparib has been shown to extend the life of relapsed ovarian cancer patients with mutations in BRCA1 and BRCA2, by nearly 13 months, when used as a maintenance therapy. 

Olaparib belongs to a group of cancer treatments called PARP-inhibitors, which work by blocking PARP proteins that are involved in a different DNA repair pathway to the one the BRCA genes affect. This causes an accumulation of DNA repair mistakes leading to the death of cancer cells. An international group of researchers treated women affected by relapsed ovarian cancer with olaparib and followed them up for over five years to measure the impact of the drug on their survival.
  
The authors concluded that: 'Olaparib provided a median overall survival benefit of 12.9 months compared with placebo in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1 and 2 mutation. Although statistical significance was not reached, these findings are arguably clinically meaningful and support the use of maintenance olaparib in these patients.' 

BRCA1 and 2 gene mutations are inherited, and as BRCA proteins are normally involved in DNA repair and act as tumour suppressors, people with these mutations are more likely to get certain cancers, including breast and ovarian. While just 1.2 percent of women in general can expect to develop ovarian cancer, this number rises to 44 percent for women with certain BRCA1 mutations and 17 percent for some BRCA2 mutation carriers.  

In this SOLO2 study published in The Lancet Oncology 295 ovarian cancer patients with suspected inherited BRCA mutation who had relapsed following treatment with platinum-based chemotherapy drugs were either put on 300mg of olaparib twice a day or a placebo. The study took place in 123 medical centres in 16 countries and patients were followed up for over five years. 

Women who had taken olaparib had a median survival time of 51.7 months from the end of treatment with platinum-based chemotherapy, compared to 38·8 months for women in the placebo group. Though authors were keen to emphasise that though the finding was not statistically significant, the survival time found was longer than previously reported for ovarian cancer treatment with PARP-inhibitor bevacizumab following platinum-based chemotherapy, where patients were shown to have a median overall survival of between 3 years and 3.5 years from the start of chemotherapy.

Over a quarter (26 percent) of patients who received olaparib experienced serious events as a result of the treatment, and four percent of those patients died as a result of the treatment. 

Sources and References

  • 18/03/2021
    The Lancet Oncology
    Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
  • 19/04/2021
    Cancer Therapy Advisor
    Study reports improved outcomes with olaparib maintenance in ovarian cancer

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
10 December 2021 • 2 minutes read

FANCI gene mutation more common in ovarian cancer patients

by Francesca Gavins

Mutations in the FANCI gene have been linked to risks of ovarian cancer for the first time...

PET BioNews
News
24 September 2021 • 2 minutes read

Two-drug approach could offer hope to ovarian cancer patients

by Jen Willows

A clinical trial combining two cancer therapies has shown promising results in patients with low grade serous ovarian cancer...

PET BioNews
News
18 June 2021 • 2 minutes read

Potential new approach identified for treating BRCA-related cancers

by Christina Burke

A new class of drug could effectively treat types of breast, ovarian and prostate cancer...

PET BioNews
News
4 June 2021 • 2 minutes read

Breast cancer drug reduces the risk of recurrence by 42 percent

by Charlott Repschläger

A targeted breast cancer treatment reduces the risk of BRCA-related cancer returning or spreading after chemotherapy...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
7 May 2021 • 2 minutes read

PARP inhibitor is most effective in ovarian cancer patients with DNA repair mutations

by Emma Bunting

New research suggests mutations in multiple DNA repair genes can determine how well ovarian cancer patients will respond to the PARP inhibitor, rucaparib...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
2 October 2020 • 2 minutes read

Precision cancer drug targets DNA repair

by Dr Melania Montes Pérez

A new anti-tumour drug that prevents cancer cells from repairing their DNA shows promising results in an early-stage clinical trial...

PET BioNews
News
1 May 2020 • 2 minutes read

Breast and ovarian cancer drug repurposed to treat prostate cancer

by Javier Bautista

A drug already used to treat breast and ovarian cancer can also significantly delay the progression of prostate cancer...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
20 March 2020 • 2 minutes read

Predicting patients benefits from new ovarian cancer treatment

by Jennifer Frosch

Analysing the tumour genome and cancer microenvironment can predict an ovarian cancer patient's response to a novel immune-PARP combination treatment, according to a new study...

PET BioNews
News
26 July 2019 • 2 minutes read

NHS approves earlier use of 'game-changing' ovarian cancer drug

by Dr Nicoletta Charolidi

Women in England with advanced ovarian cancer will now have access to a drug that could help halt the progression of their disease much earlier in their course of treatment...

PET BioNews
News
26 October 2018 • 2 minutes read

Ovarian cancer drug olaparib slows recurrence and cuts deaths

by Dr Loredana Guglielmi

A drug to treat ovarian cancer has shown promising results in a clinical trial, delaying signs of relapse and reducing chances of death. The drug olaparib, a PARP inhibitor, was used in patients with BRCA-mutated advanced ovarian cancer...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Key gene associated with Alzheimer's disease identified

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

5 July 2022 • 1 minute read

Anorexia in pregnancy linked to increased risk of complications

5 July 2022 • 2 minutes read

Pregnancy after breast cancer treatment does not increase risk of recurrence

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

4 July 2022 • 2 minutes read

USA scrambles to understand implications of Roe v Wade on fertility industry

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856